3 of the year’s most notable FDA nods

The agency has granted approvals steadily in the first part of the year, including nods for several breakthrough therapies.

By Meagan Parrish • June 27, 2025

CDC panel, newly remade by RFK Jr., questions vaccine evidence

New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at other established shots, like those for measles and hepatitis B.

By Delilah Alvarado • June 26, 2025

Explore the Trendline➔

Commercialization, marketing and social media

As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

By PharmaVoice staff

Biopharma is on edge about NIH funding cuts and what the future holds for research

Proposed cuts to public funding for early science have led to an outcry in scientific circles. For biopharma leaders, the effects are still up in the air.

By Michael Gibney • June 26, 2025

After myriad failures, a new wave of ALS drugs approaches

Several drugmakers anticipate trial results and FDA submissions in 2025 and 2026, including some still overcoming past failures.

By Amy Baxter • June 25, 2025

Biogen scores Cannes Festival win with dark humored campaign

The company’s unique campaign for a rare, terminal illness nabbed millions of views and a spot on the main stage at the Cannes Lions Festival of Creativity.

By Alexandra Pecci • June 24, 2025

Megablockbusters are the holy grail. Here’s how drugmakers are getting there.

More drugs surpassed $10 billion in revenue last year than ever before.

By Amy Baxter • June 23, 2025

Is DTC pharma advertising coming to an end?

A bill introduced in Congress fulfills a Trump administration goal of ending direct pharma ads to patients.

By Amy Baxter • June 18, 2025

FDA to speed reviews for drugs supporting ‘national interests’

A new pilot program announced by FDA Commissioner Dr. Martin Makary would award vouchers that could cut drug reviews to one or two months — but only for products that meet a special criteria.

By Jonathan Gardner • June 18, 2025

How a patient group tackled research diversity for one disease and triggered change for pharma

A policy win by the Foundation for Sarcoidosis Research has built momentum for other shifts that could bolster diversity in clinical trials.

By Meagan Parrish • June 17, 2025

Locked in a federal stalemate, states take PBM reform into their own hands

Arkansas is leading the nation in banning PBMs from owning pharmacies, as other states advance new restrictions.

By Amy Baxter • June 16, 2025

Will pharma finally score a policy win for 340B?

The industry is awaiting guidance on a rebate approach to the contentious drug discount program for hospitals and aiming for tighter oversight.

By Kelly Bilodeau • June 16, 2025

A day in the life of GSK’s U.S. president

How Maya Martinez-Davis juggles life on the go during a busy year for new drug launches.

By Meagan Parrish • June 13, 2025

Can ‘reputational pull’ save biotech from pharma’s image problem?

A reputation is tough to build and easy to bruise. For drugmakers stuck in reputational limbo, embracing a clear direction and forward-thinking strategy can foster a rosier image.  

By Michael Gibney • June 12, 2025

Pharma’s wins and losses in the budget bill

Key pharma reforms are up in the air as Republicans battle over their mammoth legislation that includes significant healthcare spending cuts.  

By Amy Baxter • June 11, 2025

The former Wall Street analyst shaping Novartis’ big-picture strategy

Ronny Gal, chief strategy and growth officer at Novartis, is guiding the company into a new era shaped by science-minded M&A and a slimmed-down pivot.

By Michael Gibney • June 10, 2025

COVID vax restrictions may not hamper uptake — but the market is still under pressure

If insurers stop covering the shots and approvals become more restrictive, the most recent policy shifts could heap more challenges onto pharma’s vaccine space. 

By Alexandra Pecci • June 10, 2025

The mindfulness of medicine development: How scientists are driving the next wave of medical innovations

For millions of patients, the development of a new treatment or vaccine can be life-changing.

June 9, 2025

The biggest obesity deals of 2025 so far

Three pharma giants are snapping up new assets to find stronger footing in the quickly shifting weight loss market.

By Amy Baxter • June 9, 2025

With ADCs on the rise, drugmakers embrace a new oncology pillar

A slow ascent for more than two decades has given way to a sharp rise in important ADC readouts, marking a milestone era for targeted treatments.

By Michael Gibney • June 6, 2025

FDA’s Elsa AI is here, and the industry has questions

The agency has provided few details about its AI pilot as it makes moves on its “aggressive timeline” for rollout.  

By Amy Baxter • June 5, 2025

Biotech CEO confidence hits rock bottom amid policy shifts

A new survey sheds light on the way early-stage company leaders are grappling with regulatory headwinds.

By Meagan Parrish • June 4, 2025

Sanofi to acquire Blueprint for up to $9.5B

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost to its immunology business.

By Jacob Bell • June 3, 2025

How leading oncology drugmakers set the stage for future advances

Drugmakers like J&J and Astellas are looking beyond today’s cancer treatments for the windows of opportunity decades down the road.

By Michael Gibney • June 3, 2025

The MAHA agenda won’t include expanding GLP-1 coverage — for now

Despite axing a Biden-era proposal for government coverage of obesity drugs, health officials have signaled a potential path forward.

By Amy Baxter • June 2, 2025

AbbVie’s ADC win shows how pharma can break through in solid tumors

 An oncology pivot recently paid off for the large pharma, which scored a milestone nod for its lead ADC.

By Meagan Parrish • May 30, 2025